.jetcityimage/iStock Content via Getty Images Morgan Stanley has picked Eli Lilly (NYSE: LLY) as its best biopharma pick for 2025 as well as ranked one more 9 labels in the room as overweight. The financial investment banking company stated in a keep in mind that it continues to strongly believe “diabesity is actually set to end up being.